Patricia Inácio, PhD, science writer —

Aerovate Therapeutics‘ AV-101, an inhaled formulation of imatinib for treating pulmonary arterial hypertension (PAH), was well tolerated in healthy adult volunteers enrolled in a Phase 1 trial. Study data also indicate AV-101, which delivers the medication directly to the lungs, reduced its systemic (whole body) exposure. This is…

The levels of blood-circulating inflammatory molecules differ between men and women with pulmonary arterial hypertension (PAH) and correlate with disease severity, a study suggests. Notably, the levels of two proteins — called IL-6 and MIP-1alpha — were predictors of poorer survival statistics. These findings suggest that patient stratification may…

A first patient in the U.S. has been dosed in a Phase 2b trial testing Respira Therapeutics‘ inhaled medicine-device combination product, called RT234, as a therapy for pulmonary arterial hypertension (PAH). The trial (NCT04266197), dubbed VIPAH-PRN, for Vardenafil Inhaled for Pulmonary Arterial Hypertension – PRN, will test…

A bilateral or double lung transplant can rescue heart function in children and adolescents with pulmonary hypertension (PH), a U.S. single-center study reports. Specifically, a transplant was found to effectively normalize right ventricular (RV) function of the heart in PH patients up to age 21. Additionally, RV dysfunction prior to…

Levels of fractional exhaled nitric oxide (FeNO) — a measure of how much nitric oxide a person exhales — may help diagnose pulmonary hypertension in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD), a Chinese study suggests. Nitric oxide, called NO, is a vasodilator that helps…

Claritas Pharmaceuticals now has exclusive worldwide rights to develop and market R-107 — a liquid form of nitric oxide — for the treatment of pulmonary diseases such as pulmonary arterial hypertension (PAH), acute respiratory distress syndrome (ARDS), and persistent pulmonary hypertension of the newborn (PPHN). In its announcement…

Elevated levels of three blood proteins — AMBP, LPL and glyoxalase I — may help identify and distinguish people with pulmonary hypertension linked to heart failure with preserved ejection fraction, called HFpEF-PH, from those with pulmonary arterial hypertension or PAH, a study suggests. Differentiating between the two is key,…

OxiWear has raised $1.25 million in funding to support the final steps in the commercialization of its ear-wearable device, designed to continuously monitor blood oxygen levels in people with pulmonary hypertension (PH). The funding round, initially with a target of $750,000, was well “oversubscribed,” the company reported in…

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Yutrepia (treprostinil), previously known as LIQ861, as an inhalation treatment for pulmonary arterial hypertension (PAH), its developer Liquidia announced. Tentative approval means that Yutrepia has met all regulatory standards regarding quality, safety, and efficacy required for approval in the U.S. Because…

A six-month at-home rehabilitation program can help improve respiratory muscle strength and physical endurance, while promoting better quality of life, in people with pulmonary arterial hypertension (PAH) That finding from a small clinical trial revealed benefits extending to six months after the end of the program, and suggests this…

PulmoSIM Therapeutics has joined with scientists at National Jewish Health hospital and Brown University to advance PT001, its investigational and potentially disease-modifying therapy for pulmonary arterial hypertension (PAH), into clinical trials. The partnership follows PT001 being designated an orphan drug by the U.S. Food and Drug Administration (FDA). Orphan drug status…

U.S. veterans infected with the human immunodeficiency virus (HIV) — the virus that causes AIDS — are at higher risk of pulmonary hypertension (PH), according to a large study in this population. “HIV infection had a direct effect on incident pulmonary hypertension among US veterans,” including those with no history…